

day 0
dose 1
day 14
dose 2
day 21
ELISPOT
Splenocyte Restimulation with:
KRAS G12D 18-mer
IFNg SFC / 1x10^6 splenocytes
1000
750
500
250
0
untreated
Soluble KRAS G12D + Amph-CpG
Amph-KRAS G12D + Amph-CpG
Soluble KRAS G12D + polyIC

FIG. 1



day 0
dose 1
day 14
dose 2
day 21
ELISPOT
untreated
Soluble KRAS G12R or G12V + CpG
Amph-KRAS G12R or G12V + Amph-CpG
Soluble KRAS G12R or G12V + polyIC
KRAS G12R 18-mer
IFNg SFC / 1x10^6 splenocytes
500
400
300
200
100
0
KRAS G12V 18-mer
IFNg SFC / 1x10^6 splenocytes
150
100
50
0

FIG. 2



IFNg+ CD8 Response in PBMC: Restimulation with G12D 4-21 Overlapping 9-mers
day 0
dose 1
day 14
dose 2
day 21
Intracellular Cytokine Staining (blood)
%IFNg+ among CD8 T cells
1.00
0.75
0.50
0.25
0.00
Soluble WT + CpG
Soluble KRAS G12D + CpG
Amph-KRAS G12D + Amph-CpG

FIG. 3



day 0
dose 1
day 7
dose 2
day 14
dose 3
day 21
ELISPOT
KRAS G12D 9-mers
IFNg SFC / 1x10^6 splenocytes
300
200
100
0
untreated
Soluble KRAS G12D + CpG
Amph-KRAS G12D + Amph-CpG
day 0
dose 1
day 14
dose 2
day 21
ELISPOT
KRAS G12D 18-mer
IFNg SFC / 1x10^6 splenocytes
1000
750
500
250
0

FIG. 4



Weekly: G12D 18-mer Restimulation
day 0
dose 1
day 7
dose 2
day 14
dose 3
day 21
Splenocyte CBA
ng/ml
100
80
60
40
20
0
IL-12
TNFa
IFNg
MCP-1
IL-10
IL-6
Biweekly: G12D 18-mer Restimulation
day 0
dose 1
day 14
dose 2
day 21
Splenocyte CBA
ng/ml
100
80
60
40
20
0
IL-12
TNFa
IFNg
MCP-1
IL-10
IL-6
untreated
Soluble KRAS G12D + CpG
Amph-KRAS G12D + Amph-CpG

FIG. 5



Cys
Tyr
Lys
Leu
Val
Val
Val
Gly
Ala
Asp
Gly
Val
Gly
Lys
Ser
Ala
Leu
Thr
Ile

FIG. 6




FIG. 7